{"disease":{"id":"t-lgl-leukemia","name":"t lgl leukemia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07019766","title":"National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia","phase":"","overall_status":"RECRUITING","enrollment_count":9999,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT05225584","title":"Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"Kymera Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06530550","title":"PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":51,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06530576","title":"Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06716658","title":"JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT04453345","title":"TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":42,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}